ArticleF1000Research2025
Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary open-angle glaucoma (POAG) is a major cause of irreversible blindness worldwide, characterized by progressive optic neuropathy and loss of retinal ganglion cells (RGCs). Although lowering intraocular pressure (IOP) remains the mainstay of glaucoma management, many patients continue to experience vision loss, underscoring the need for adjunctive neuroprotective approaches. In Ayurveda, Methods: This is an open-label, two-arm, parallel-group randomized controlled trial with a 2:3 (control: intervention) allocation ratio. A total of 50 previously or newly diagnosed POAG patients (IOP < 30 mmHg) are planned for enrollment. The control group receives the conventional standard of care alone, whereas the intervention group receives standard care plus RF (2.5 g, taken orally twice daily) and SP eye drops (1 drop, four times daily), administered for 90 days with a further 90-day follow-up. Primary outcomes include changes in optic nerve function measured by visual field indices (mean deviation (MD), pattern standard deviation (PSD), visual field index (VFI)) and retinal nerve fiber layer (RNFL) thickness, while secondary outcomes include IOP changes. Results: Participant recruitment and data collection are ongoing. Final outcomes will be disseminated in peer-reviewed journals. Conclusions: If shown to be effective, the combined RF and SP eye drops could enhance neuroprotection and further control IOP in POAG, thereby addressing a significant need in current glaucoma therapy. This trial may provide a foundation for larger-scale investigations into integrative treatments for glaucoma management. Trial Registration: Clinical Trial Registry of India (CTRI) no. CTRI/2023/06/053681, dated 08.06.2023.Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2023/06/053681
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.